Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Faessel Publishing LLC
Dr.Faessel@onthemar.com

The Growth Engine of the 21st Century: Hyperdigitization*

Growth to be 25% of Global GDP by 2020*

Midas Medici Group Holdings, Inc. (MMED) OTCBB $2.50

Undiscovered, undervalued and trades by appointment, but nevertheless the story (and management) has credentials… a plan and “they” are performing.

(MMED) is a green IT company that supplies mid-sized and select enterprises and institutions with leading-edge IT solutions in the fields of virtualization, cloud computing, disaster recovery and data management. (MMED) also works with utilities and other institutions to transform the electric grid through efficiencies using Smart Grid digital technologies. Read the rest of this entry »

Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Faessel Publishing LLC
Dr.Faessel@onthemar.com

NIVS IntelliMedia Technology Group, Inc. (NIV) AMEX $2.67

Market-cap $130 million

 Mighty China Telecom (CHA) NYSE has selected the NIVS IntelliMedia (NIV) “E3″ model mobile phone as one of its key 3G promotion products. While relatively small and not yet on the radar screen of most investors, (NIV) is very profitable, with a low P/E ratio of 4, a Price to Sales ratio of only 0.40, with quarterly revenue (year over year) growing at approximately 59%.  Having its product selected by China Telecom should set (NIV) on the path not only for more of the same, but for an ever-increasing bulge in these key valuation metrics.  Read the rest of this entry »

Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Faessel Publishing LLC
Dr.Faessel@onthemar.com  

Strikingly Undervalued Metrics while Maintaining Exceptional Profit & Revenue Growth  

Bohai Pharmaceuticals Group Inc.  (OTCBB/OTCQB: BOPH) $2.20   

Unless you’ve just recovered consciousness out of a 10-year coma or just back from a trip exploring the cosmos you know that China is “the” economic phenomena of this new century. Chinese companies are benefiting from both macro and micro trends that are the making of historic, tremendously bullish scenarios. This profitable, undervalued, and undiscovered Chinese pharmaceutical company fits that description to a T…  

(BOPH) manufactures and distributes traditional Chinese herbal medicines and other products that are used for common health problems such as rheumatism, rheumatoid arthritis, respiratory diseases, viral infections, gynecological diseases and cardiovascular issues. Key is that the company’s 15 traditional pharmaceutical products carry the U.S. equivalent of government licenses and certain key products are “protected” and one has a patent lasting 20 years.   Read the rest of this entry »

Arthur Goldgaber
Market Analyst
SmallcapInsights.com

To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.

Follow

Get every new post delivered to your Inbox.